All those in the review who described small snooze period — defined in the examine as six hours or fewer — had elevated ranges … Read more
Who’s going to acquire the mRNA bake-off? How worrisome is the Delta variant? And why do drug names audio like Raffi lyrics?
We cover all that and additional this 7 days on “The Readout LOUD,” STAT’s biotech podcast. To start with, we dive into the likely of mRNA, a technologies that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then, STAT’s Helen Branswell joins us to explore the point out of the pandemic, the implications of the Delta variant, and the discussion all around booster photographs. We also dissect the week’s news in biotech,
Biogen and Ionis report constructive topline scientific facts on investigational Alzheimer’s illness remedy at AAIC
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 26, 2021 /PRNewswire/ — Biogen Inc. (Nasdaq: BIIB) and Ionis Prescription drugs, Inc. (Nasdaq: IONS) declared right now that topline facts from a Section 1b placebo-controlled, several ascending dose medical review showed that BIIB080/IONIS-MAPTRx satisfied its key objective of basic safety and tolerability in patients with gentle Alzheimer’s disorder. The review shown sturdy time and dose dependent decreasing of tau protein in cerebrospinal fluid (CSF) about the a few-thirty day period treatment interval and sustained reductions all through the six-month post-cure interval.
In clients obtaining BIIB080, there ended up dose-dependent decreases in